Home
Artbio, Inc.

Artbio, Inc. Market Share Analysis for March 2026

learn about how artbio is redefining cancer care through a new class of alpha radioligand therapies and building an ecosystem to maximize their potential.

Industry: N/A

Domainartbio.com

Year Founded2021

Employees51 - 200

Annual Revenue$1M - $2M

Artbio, Inc.

Artbio, Inc. (including company regionals)

artbio.com

See more website traffic and engagement information

Artbio, Inc. Revenue up to March 2026 is 1M - 2M

revenue generated by Artbio, Inc. top domains

Artbio, Inc. top domains revenue over 3 years

Revenue for Artbio, Inc. top domains

artbio.com1M - 2M

See more with Sales Intelligence

Total visits to Artbio, Inc.'s top domains

Understand Artbio, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

artbio.com3.8K

See more with Sales Intelligence

Avg. visit duration in Artbio, Inc.'s top domains

Analyze Artbio, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

artbio.com00:00:14

See more with Sales Intelligence

Avg. pageviews on Artbio, Inc.'s top domains

See how Artbio, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

artbio.com1.33

See more with Sales Intelligence

Artbio, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Artbio, Inc.

These are the website technologies, by industry, used by Artbio, Inc. top domains

Mobile (2)

Meta Viewport

Recruitment (2)

Lever

Content Management System (1)

Netlify

Conversion & Analytics (1)

Google Analytics

More Technologies

2

See all

News & Signals from Artbio, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsARTBIO, Inc. is developing AB001.ARTBIO is developing AB001, a Pb212 prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, for the treatment of metastatic castration resistant prostate cancer (mCRPC)

NewsARTBIO, Inc. received financing of $132M in Series B on Jul 29th '25.CAMBRIDGE, MA, USA and OSLO, Norway I July 29, 2025 I ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs) to treat a range of cancers, today announced the closing of a $132 million Series B financing co-led by new investors Sofinnova Investments and B Capital along with a life sciences dedicated investment fund that invested previously.

NewsARTBIO, Inc. hires Margaret Yu as chief medical officer.Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO).